Retreatment of patients surviving cancer-free 2 or more years after initial treatment of small cell lung cancer

Chest

Volumn 110, Issue 1, 1996, Pages 165-171

  Chute, John P ^b,c   Kelly, Michael J ^a   Venzon, David ^a   Williams, John ^b   Roberts, Allen ^b,c   Johnson, Bruce E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

carcinoma; lung neoplasm; recurrence; small cell; survivors; treatment outcome

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; LOMUSTINE; METHOTREXATE; MONOCLONAL ANTIBODY; PROCARBAZINE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; LUNG RESECTION; LUNG SMALL CELL CANCER; MALE; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0029887189     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.110.1.165     Document Type: Article

References (32)

1. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992; 20:1434-41
2. Albain KS, Crowley JJ, Livingston RB. Long-term survival and toxicity in small cell lung cancer: expanded Southwest Oncology Group experience. Chest 1991; 99:1425-32
3. Johnson BE, Linnoila I, Williams JP, et al. Risk of second aerodigestive cancers increases in patients who survive free of small-cell lung cancer for more than 2 years. J Clin Oncol 1995; 13: 101-11
4. Heyne KH, Lippman SM, Lee JJ, et al. The incidence of second primary tumors in long-term survivors of small-cell lung cancer. J Clin Oncol 1992; 10:1519-24
5. Lassen U, Osterlind K, Hansen M, et al. Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years: an analysis of 1,714 consecutive patients. J Clin Oncol 1995; 13:1215-20
6. Souhami RL, Law K. Longevity in small cell lung cancer: a report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. Br J Cancer 1990, 61:584-89
7. Batist G, Hide DC, Zabell A, et al. Small cell carcinoma of lung: reinduction therapy after late relapse. Ann Intern Med 1983; 98: 472-74
8. Albain KS, Crowley JJ, Hutchins L, et al. Predictors of survival following relapse or progression of small cell lung cancer: South-west Oncology Group Study 8605 report and analysis of recurrent disease data base. Cancer 1993; 72:1184-91
9. Postmus PE, Berendsen HH, Van Zandwijk N, et al. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term therapy. Eur J Cancer Clin Oncol 1987; 9:1409-11
10. Turrisi AT III, Glover DJ, Mason BA. A preliminary report: concurrent twice-daily radiotherapy plus platinum-etoposide chemotherapy for limited small cell lung cancer. lnt J Radiat Oncol Biol Phys 1988; 15:183-87
11. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 1993; 11:336-44
12. McCracken JD, Janaki LM, Crowley JJ, et al. Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group study. J Clin Oncol 1990; 8:892-98
13. Johnson DH, Turrisi AT III, Chang AY, et al. Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: a pilot study of the Eastern Cooperative Oncology Group. J Clin Oncol 1993; 11:879-84
14. Johnson DH, Kim K, Turrisi AT III, et al. Cisplatin and etoposide plus concurrent thoracic radiotherapy administered once versus twice daily for limited-stage small cell lung cancer: preliminary results of an intergroup trial. Proc Am Soc Clin Oncol 1994; 13:333
15. Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987; 316:912-18
16. Bunn PA, Lichter AS, Makuch RW, et al. Chemotherapy alone or chemotherapy with chest irradiation therapy in limited stage small cell lung cancer. Ann Intern Med 1987; 106:655-62
17. Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small cell lung cancer. J Clin Oncol 1994; 10:2022-34
18. Johnson BE, Bridges JD, Sobczek M, et al. Patients with limited stage small cell lung cancer treated with concurrent twice daily chest radiation therapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, vincristine. J Clin Oncol (in press)
19. Cohen MH, Ihde DC, Bunn PA, et al. Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma. Cancer Treat Rep 1979; 63:163-70
20. Brower M, Ihde DC, Johnston-Early A, et al. Treatment of extensive stage small cell bronchogenic carcinoma: effects of variation in intensity of induction chemotherapy. Am J Med 1983; 75:993-1000
21. Ihde DC, Deisseroth AB, Lichter AS, et al. Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive stage small-cell lung cancer. J Clin Oncol 1986; 4:1443-54
22. Catane R, Lichter A, Lee YJ, et al. Small cell lung cancer: analysis of treatment factors contributing to prolonged survival. Cancer 1981; 48:1936-43
23. Cohen MH, Creaven PJ, Fossieck BE, et al. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treatment Reports 1977; 3:349-54
24. Wittes RE. Appendix A: grading of toxicity. In: Manual of oncologic therapeutics 1989/90. Philadelphia: JB Lippincott, 1989; 445-48
25. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81
26. Cox DR. Regression models and life tables (with discussion). J R Stat Soc 1972; 34:187-220
27. Cox DR. Analysis of binary data. London: Chapman & Hall, 1970; 48-50
28. Kelley M, Johnson BE, Avis I, et al. Complete response in a patient with small cell lung cancer treated on a phase II trial using a murine monoclonal antibody (2A11) directed against gastrin releasing pepride. Proc Am Soc Clin Oncol 1993; 12:339
29. Spiegelman D, Maurer LH, Ware JH, et al. Prognostic factors in small cell carcinoma of the lung: an analysis of 1521 patients. J Clin Oncol 1989; 3:344-54
30. Longo DL, Duffey PL, Young RC, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992; 10:210-18
31. Valagussa P, Brambilla C, Zambetti M. Salvage treatments in relapsing resectable breast cancer. Recent Results Cancer Res 1989; 115:69-76
32. Paccagnella A, Chiarion-Sileni V, Soesan M, et al. Second and third responses to the same induction regimen in relapsing patients with multiple myeloma. Cancer 1991; 68:975-80